Investor Presentation on the Financial Results of the Company for the quarter ended June 30, 2026

August 5, 2026 BSE Limited The National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, 25th Floor, Dalal Street, Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 001 Scrip Code: 524558 Scrip Code: NEULANDLAB; Series: EQ Dear Sir/Madam, Sub: Investors/Analysts Presentation Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the presentation to the Investors/ Analysts on the Financial Results of the Company for the quarter ended June 30, 2026. The presentation is also being uploaded on the website of the Company at www.neulandlabs.com. This is for your information and records. Thanking You, Yours sincerely, For Neuland Laboratories Limited Sarada Bhamidipati Company Secretary Encl: As above Neuland Laboratories Limited Investor Presentation Q1FY27 SAFE HARBOUR Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements“. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Table of Content Q1FY27 Highlights Company Overview Business Strategy Our Businesses Shareholder Information Q1FY27 Company Business Our Shareholder Annexure Annexure Highlights Overview Strategy Businesses Information Q1FY27 Highlights Management Commentary SAHARSH DAVULURI, CEO & MD “Q1 FY27 was broadly in line with our expectations with encouraging performance from both CMS & GDS businesses and represents a good start to the year. While Commercial Products contributed to most of the revenue, we are seeing exciting developments in terms of the pipeline projects. The depth of customer conversations today is significantly stronger, and we are increasingly engaging on broader capability-led discussions rather than individual projects alone. Internally our focus now is on ensuring that we deliver consistently, build customer confidence and establish the foundation for long-term partnerships. Even as we have invested significantly over the last three years and all our significant Capex projects are proceeding according to plan, I believe the intensity of our investments will further increase based on the opportunities that available to us. ” Q1FY27 Business Overview CMS revenues driven by commercial molecules. Growth in new projects orders which will be delivered over the course of this and next financial years. Traction from Innovators with peptides molecules in pipeline. In Prime segment Ezetimibe and Mirtazapine were the key molecules. Ezetimibe likely to drive growth of the Prime segment. Specialty business driven by Aripiprazole Sterile, Donepezil and Apixaban. Financial Highlights Working capital days of sale at 84 days in Q1FY27 as against 137 days in Q4FY26, mainly on account of decrease in receivables. Capex outflow of Rs. 122 Cr in Q1FY27. Q1FY27 Financial Highlights Total Income EBITDA PAT EPS (Rs. Cr) (Rs. Cr) (Rs. Cr) (Rs.) 40.5% 30.4% 350.0 26.9% 22.7% 35.5% 18.7% 300.0 250.0 .2 19.0% 4 200.0 2 6 9 6 .0 0 3 .6 1 5 8 .7 4 4 7 .8 8 1 .0 1 .2 4.0% 9 .6 5 1 0 .5 8 .9 1 3 1 .1 511 005 .00 0.. 00 4. 7 .3 5 .6 9 4 .09.0% 4 .7 4 1 7 .0 1 2 .5 7 5 .1 3 .5 6 1 .4 1 1 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Financial Highlights • Total Income for Q1FY27 at Rs. 650.1 crore (116.3% YoY) • EBITDA for Q1FY27 at Rs. 231.1 crore (448.2% YoY) • EBITDA Margin for Q1FY27 at 35.5% (increased by 2150 bps YoY) • PAT for Q1FY27 at Rs. 147.4 crore (975.0% YoY) • Net Debt stood at Rs. (308.5) crore as at Q1FY27 end compared to Rs. (164.7) crore as at Q1FY26 end and Rs (156.8) crore as at Q4FY26 end Key Balance Sheet Metrics Current Ratio(x) ROCE % Fixed Asset Turnover (x) Debt to Equity (x) 7 .1 1 .2 4 .2 1 .2 2 .2 % 3 .1 % 8 .2 3 % 9 % 1 .6 2 7 .2 1 .3 3 .2 6 .2 2 .3 1 .0 1 .0 1 .0 1 .0 1 .0 FY23 FY24 FY25 FY26 Q1FY27 FY23 FY24 FY25 FY26 Q1FY27 FY23 FY24 FY25 FY26 Q1FY27 FY23 FY24 FY25 FY26 Q1FY27 Particulars (Rs Cr) Mar-23 Mar-24 Mar-25 Mar-26 Jun-26 Shareholder’s Funds 988.4 1267.5 1,517.8 1,865.9 2,013.2 Net Debt* 63.0 -32.6 -228.7 -156.8 -308.5 Tangible Assets (including CWIP)** 511.2 575.4 698.3 1,002.9 1,116.9 Working Capital 463.0 525.4 440.6 773.0 600.5 *Net debt includes investment in Mutual Fund in previous years. **Tangible assets includes investment property in previous years. Key Operating Metrics Q1FY27 Top 10 & Top 5 Products Top 10 & Top 5 Customers Segment revenue Top 10 Prime Specialty Top 10 Top 5 CMS Others Top 5 7% 4% 6% 6% 6% 100% 99% 99% 96% 80% 96% 44% 79% 60% 65% 61% 72% 68% 67% 70% 11% 41% 40% 8% 8% 26% 22% 18% 18% Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Prime Specialty CMS Overall Company Prime Specialty CMS Overall Company • CMS business caters to Innovator customers on an exclusive basis, developing and manufacturing APIs/Intermediates in line with rigorous customer expectations hence is highly concentrated in terms of customers • Specialty segment works on complex products and technologies, hence has a focused approach towards select customers CMS – Revenue Split & Number of Active Projects Rs. Cr YoY Movement No. of active CMS projects Q1 FY27 Pre-Clinical P-1 P-2 P-3 Pre-Reg/Reg Commercial Grand Total API 15 13 13 5 4 9 59 Intermediate 2 10 7 8 3 10 40 Grand Total 17 23 20 13 7 19 99 14 20 Q1 FY26 Pre-Clinical P-1 P-2 P-3 Pre-Reg/Reg Commercial Grand Total Q1 FY26 Q1 FY27 API 15 14 13 5 4 9 60 Development Commercial Intermediate 5 8 7 4 4 10 38 Grand Total 20 22 20 9 8 19 98 Rs. Cr QoQ Movement Q1 FY25 Pre-Clinical P-1 P-2 P-3 Development Commercial Grand Total API 8 8 12 3 8 8 47 Intermediate 9 4 11 4 6 10 44 291 Grand Total 17 12 23 7 14 18 91 120 13 19 23 43 20 Q1 FY24 Pre-Clinical P-1 P-2 P-3 Development Commercial Grand Total API 14 5 10 4 8 8 49 Q1FY26 Q2FY26 Q3 FY26 Q4 FY26 Q1 FY27 Intermediate 6 4 6 4 7 11 38 Development Commercial Grand Total 20 9 16 8 15 19 87 • Pre-clinical to P-3: Neuland generates revenue by process research & development as well manufacturing quantities for clinical trials • *Pre-Reg/Reg: Phase-3 complete; Molecules filed but not yet commercial (Earlier labelled as ‘Development’) or where customer working towards adding Neuland as a second source for a commercial molecule • Commercial: Neuland generates revenues by manufacturing APIs for commercial novel molecules for innovators • Steady trend in molecules transitioning from clinical phases to commercialisation resulting in increase in revenue from commercial products 10 Company Overview Company Overview Manufacturing of generic Generic APIs non-exclusive APIs Established in Business 1984 verticals Contract development and CDMO Services 40 years in API manufacturing manufacturing of NCE API and development Total reactor volume of 12,26,000 Liters Facilities Supported 3 NDA Expertise in manufacture of 3 cGMP Manufacturing facilities Inspected by filings and 18 IND Deuterated molecules, Cyanation, Chemical R&D Labs USFDA, EMA, filings [Showing first 8,000 characters — download PDF for full document]